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Annexin 1 has been shown to participate through its unique N-terminal domain in the recruitment and activation of leukocytes at sites of
inflammation. Peptides derived from this domain are true mimetics of the annexin 1 action in all inflammation models tested and most likely serve
as the active entities generated at sites of inflammation. To elucidate mechanisms underlying peptide generation we used isolated blood leukocytes
and endothelial cell monolayers. We show that following endothelial adhesion, annexin 1 was externalized from leukocytes and rapidly cleaved.
Addition of purified annexin 1 to degranulating leukocytes resulted in the truncation of annexin 1, which seemed to depend on the proteolytic
activity of human leukocyte elastase (HLE). The capacity of elastase to proteolytically cleave annexin 1 was confirmed using both purified
annexin 1 and HLE. The identification of annexin 1 as a substrate for HLE supports the model in which annexin 1 participates in regulating
leukocyte emigration into inflamed tissue through N-terminal peptides generated at inflammatory sites.
© 2006 Elsevier B.V. All rights reserved.Keywords: Calcium; Endothelial cell; Inflammation; Elastase1. Introduction
A key step in inflammation is the migration of neutrophils
from the circulating blood into the inflamed tissue. To ensure
precise regulation, a complex network of soluble and surface-
bound mediators controls leukocyte rolling on and adhesion to
the endothelium as well as the subsequent transendothelial
passage into the extravascular tissues [1]. Annexin 1, a member
of the annexin family of Ca2+/lipid-binding proteins [2], has
received considerable attention over the past two decades as an
anti-inflammatory mediator, since it was shown to exert anti-
inflammatory activities in several models of inflammation, e.g.
by inhibiting neutrophil extravasation [3]. The physiologic
importance of its extracellular activity has been strengthened by
the recent identification of annexin 1 as a specific ligand for the
formyl peptide receptor family of chemoattractant receptors [4–
6]. It was shown that the anti-migratory property of annexin 1 on
the transendothelial migration of granulocytes is at least in part
due to receptor desensitization. Receptor activation and⁎ Corresponding author. Tel.: +49 251 8356722; fax: +49 251 8356748.
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doi:10.1016/j.bbamcr.2006.08.041desensitization is mediated through the N-terminal part of the
annexin 1 molecule [4,5], most likely explaining previous
observations that proteolytic removal of the N-terminal part
causes inactivation of annexin 1 [7], whereas synthetic peptides
corresponding to this part of annexin 1 retain the full
pharmacologic activity [8].
Annexin 1 is highly susceptible to proteolytic cleavagewithin
the N-terminal domain where cleavage sites for proteases have
been identified. Proteolytic cleavage of precursors is a common
step in the activation of bioactive molecules. Many molecules
relevant to inflammation such as cytokines and their receptors
contain cleavage sites for neutrophil serine proteases and are
their natural substrates [9,10]. Modulation of the bioactivity
through released neutrophil proteases might be a potent
mechanism to control the extent of inflammatory processes.
Human leukocyte elastase (HLE) is a major serine protease
stored in the primary granules of polymorphonuclear neutrophils
(PMN) that are released upon PMN activation [11]. HLE has
been shown to accumulate at sites of inflammation and to
participate in inflammatory disorders such as rheumatoid
arthritis and cystic fibrosis [12]. We therefore analyzed the
sensitivity of annexin 1 to proteolytic cleavage by HLE.
Fig. 1. Release of annexin 1 upon adhesion of PMN to the EAhy monolayer.
PMN isolated from buffy coats were treated as indicated and either kept in
suspension or incubated on EAhy monolayers for 30min at 37 °C. Proteins of
the cell-free supernatants were separated by SDS-PAGE and immunoblotted
using the anti-annexin 1 polyclonal antibody r656 which recognizes both the
intact, full-length (fl) and cleaved (c) protein species. Note that in the absence of
a EAhy monolayer, annexin 1 is only externalized upon priming with 5μg/ml
cytochalasin B and subsequent fMLF stimulation of PMN. Results are
representative of at least three independent experiments.
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2.1. Reagents
Human leukocyte elastase (E.C. 3.4.21.37) was obtained from Calbiochem,
the specific human leukocyte elastase inhibitor N-methoxysuccinyl-Ala-Ala-
Pro-Val chloromethyl ketone (MeOSuc-AAPV-CMK), cytochalasin B and the
chemotactic peptide N-formyl-Met-Leu-Phe (fMLF) were purchased from
Sigma.
2.2. Cell culture
The human endothelial hybrid cell line EAhy.926 (obtained from the
German Cell Culture Collection, DSMZ, Braunschweig, FRG) was maintained
in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% FCS,
2mM glutamine and penicillin/streptomycin. Cells were cultured at 37 °C in a
humified atmosphere with 7% CO2.
2.3. Isolation of human peripheral blood PMN
PMN were isolated from buffy coats using Ficoll-Paque gradient
centrifugation [13]. Erythrocytes were removed from sedimented granulocytes
through hypotonic lysis.
2.4. Expression and purification of recombinant human annexin 1
To obtain recombinant human annexin 1, the cDNA encoding human
annexin 1 was cloned into pET23a(+) vector that has been modified to allow for
bacterial expression of untagged recombinant proteins [14]. Recombinant
annexin 1 was purified from the E. coli lysates as described in [15].
2.5. Adhesion of PMN to EAhy monolayers and detection of released
annexin 1
Mobilization assays using granulocytes adhering to EAhy monolayers were
performed essentially as described [16]. In brief, 1.5×106PMN/well in
adhesion buffer (Hanks' balanced salt solution supplemented with 1.3mM
CaCl2 and 1.3mM MgCl2) were added to EAhy grown on six-well plates or
kept in suspension. After incubation for 30min at 37 °C, supernatants were
aspirated. To remove cell surface-bound annexin 1, EAhy cells were washed
with PBS containing 5mM EDTA. Contaminating cells were removed by
centrifugation at 5000×g for 5min and proteins in the recovered cell-free
supernatants were TCA-precipitated. Equal amounts of each sample were
subjected to SDS-PAGE and subsequent Western blotting. Annexin 1 was
detected using the anti-annexin 1 polyclonal antibody r656 [17] which
recognizes both intact and cleaved annexin 1.
2.6. Annexin 1 cleavage by activated PMN
For cleavage assays using PMN and recombinant human annexin 1, 1×106
granulocytes in RPMI with addition of 20mM HEPES, were treated as
indicated. PMN were primed with 5μg/ml cytochalasin B for 1h at 37 °C. The
specific inhibitor MeOSuc-AAPV-CMK was added at a final concentration of
10μM. Subsequently, 2μg of recombinant annexin 1 were added and PMNwere
stimulated with 100nM fMLF. After 45min at 37 °C, cells were removed by
centrifugation. Equal amounts of the supernatants were TCA precipitated and
subjected to SDS-PAGE. Proteins were visualized by Coomassie staining.
2.7. In vitro cleavage of recombinant human annexin 1
Purified recombinant human annexin 1 (1μg) was incubated with
recombinant human leukocyte elastase at a final concentration of 0.3units/ml
in reaction buffer (50mM Tris, pH 7.6; 0.5M NaCl, 20mM CaCl2) with or
without the specific inhibitor MeOSuc-AAPV-CMK at a final concentration of
100μM for 1h at 37 °C. Samples were subjected to SDS-PAGE and the gels
were Coomassie-stained.3. Results
3.1. Annexin 1 is externalized and truncated upon adhesion of
PMN to endothelial cells
Isolated peripheral PMN and the human endothelial hybrid
cell line Eahy.926 were used as an in vitro model of PMN
adhesion to endothelial cell layers. Immunoblotting analysis
revealed that annexin 1 was essentially undetectable in the
supernatants of either resting PMN in suspension (Fig. 1, lane 1)
or EAhy monolayers (Fig. 1, lane 5). Treatment of non-adherent
PMN in suspension with fMLF alone was not sufficient to
induce annexin 1 externalization (Fig. 1, lane 2), whereas cyto-
chalasin priming and further stimulation with fMLF triggered
annexin 1 release to a substantial amount (lane 4). Upon PMN
adhesion to the endothelial monolayer, significant annexin 1
release was observed even in the absence of fMLF stimulation
(Fig. 1, lane 6). Whereas lysates prepared from resting PMN
only show an immunoreactive signal corresponding to the size of
the full-length 37kDa protein (not shown), a large fraction of the
annexin 1 found extracellularly had a smaller size of
approximately 33kDa, indicating rapid and effective proteolytic
cleavage.
3.2. In vitro proteolysis of purified human annexin 1 by Human
Leukocyte Elastase
Human leukocyte elastase (E.C. 3.4.21.37) is one of the
major serine proteases stored in the primary granules of PMN.
Elastase is effectively released into the extracellular milieu
following adhesion of activated PMN. To further characterize
the proteolytic activity responsible for the observed cleavage of
annexin 1, we chose to investigate the ability of annexin 1 to
serve as a direct substrate for HLE. In a first set of experiments,
we incubated bacterially expressed recombinant human annexin
1 with purified HLE. Annexin 1 obtained from the E. coli
expression system was predominantly in the full-length form
with a molecular weight of ∼37kDa and contained only minor
amounts of smaller fragments (Fig. 2). Exposure of recombinant
human annexin 1 to HLE resulted in the total loss of the 37kDa
Fig. 3. Activated PMN rapidly degrade exogenously added annexin 1. Purified
recombinant human annexin 1 (rhanx1, 2μg) was added at 37 °C to un-
stimulated PMN or PMN treated with the agents as indicated. Degranulation was
stimulated with 100nM fMLF for 45min. Cell-free supernatants were obtained
and proteins therein were subjected to SDS-PAGE and Coomassie staining. A
representative result is shown.
Fig. 2. Proteolytic cleavage of annexin 1 by HLE. Purified recombinant human
annexin 1 (rhanx1, 1μg) was exposed to 0.5μM HLE for 1h at 37 °C or left
untreated. Proteolysis of annexin 1 was analyzed by SDS-PAGE followed by
Coomassie Blue staining of the gel. The gel shown is representative of at least
three independent experiments.
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nantly of 33kDa, appeared. Addition of N-methoxysuccinyl-
Ala-Ala-Pro-Val chloromethyl ketone (MeOSu-AAPV-CMK),
a cell-permeable, non-cytotoxic inhibitor of HLE, completely
inhibited the ability of HLE to cleave annexin 1 (Fig. 2, lane 3).
The observed direct proteolytic effect of HLE on recombinant
human annexin 1 identifies annexin 1 as a substrate for HLE.
3.3. Purified annexin 1 is cleaved by PMN stimulated to
degranulate
To examine further the specificity of annexin 1 as a HLE
substrate and to confirm that HLE proteolytic activity from
activated PMN is responsible for the cleavage of annexin 1, we
next performed experiments in which purified recombinant
human annexin 1 was exposed to PMN. As shown in Fig. 3, co-
incubation of annexin 1 with PMN was not sufficient to cause
annexin 1 degradation, even when PMN were stimulated with
fMLF. Because neutrophils in suspension show only limited
degranulation, disruption of the actin cytoskeleton by cytocha-
lasin B is needed to promote elastase release from neutrophil
primary granules upon stimulation with activating mediators
such as fMLF [18–20]. We found that cleavage of extracellu-
larly added annexin 1 was indeed dependent on priming of
PMN with cytochalasin B and subsequent fMLF activation,
indicative of a controlled activation-driven process. As addition
of the HLE inhibitor MeOSu-AAPV-CMK significantly
inhibited the observed degradation of annexin 1, elastase
seemed to be the major PMN-derived protease responsible for
proteolytic cleavage of annexin 1 (see also Fig. 2).
4. Discussion
In the present study, we characterized the externalization of
annexin 1 from PMN. Significant release of annexin 1was found
only when PMN were induced to degranulate. Interestingly,
although the nonphysiological agent cytochalasin B that is
necessary for the release of primary granules from PMN in
suspension also induced externalization of annexin 1, adhesion
of PMN to endothelial cells was much more efficient. A vast
amount of the externalized protein was of smaller molecular
size, indicating rapid proteolytic cleavage by PMN-derived
proteolytic activity. We demonstrated the ability of human
leukocyte elastase to digest annexin 1. Furthermore, an elastase-
specific enzymatic activity released from activated PMN rapidlycleaved annexin 1, suggesting that extracellular cleavage of the
anti-inflammatory mediator annexin 1 can occur at sites of
inflammation.
The 37kDa protein annexin 1 belongs to the annexin family
of Ca2+ binding proteins. Whereas the core modules of annexins
are evolutionary highly conserved, the preceding N-terminal
domains vary considerably in length and sequence between
different annexins and seem to exert important regulatory
activities. Annexin 1 is highly abundant in neutrophils.
Although it is a cytosolic protein lacking a secretory signal
sequence and therefore cannot enter the classical ER/Golgi
secretion pathway, it is nevertheless found in extracellular fluids
such as human serum, with elevated annexin 1 levels occurring
particularly in inflammatory settings [21–24]. Exogenously
administered it acts as a potent anti-inflammatory agent that
limits the transendothelial migration of leukocytes [25] and
thereby the degree of inflammation, a pharmacologic property
that has been reported in many different animal models of
inflammation [26]. This vast body of literature on its anti-
inflammatory activities as well as the observation that annexin 1
deficient mice show an exaggerated inflammatory response in
both acute and chronic models of experimental inflammation
[27,28] point to the physiological relevance of extracellular
annexin 1. The finding that annexin 1 represents a novel endo-
genous ligand for all known members of the formyl peptide
receptor superfamily [4–6], heptahelical, G-protein coupled
receptors on the leukocyte surface that mediate cell activation
and chemotaxis upon binding of bacterially derived peptides of
the fMLF prototype [29], established a mechanistic basis for the
annexin 1-mediated anti-inflammatory effects.
Studies on the anti-inflammatory activity of annexin 1 both in
in vitro and in vivo models revealed that this anti-inflammatory
activity lies within the unique N-terminal part. Peptides corres-
ponding to this sequence act as mimetics that retain the full
pharmacologic property of the whole protein [8], and they also
serve as ligands for the formyl peptide receptors. Annexin 1 is a
relatively unstable molecule and cleavage of the pharmacolog-
ically active N-terminal part is commonly observed [30]. Inte-
restingly, a vast amount of the protein externalized upon contact
of PMN with the endothelial cells is of smaller molecular size,
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annexin 1 crystal structure discovered that this N-terminal domain
is mostly buried in the protein core and therefore most likely not
accessible for FPR interaction [31]. Therefore, N-terminal
peptides released by limited proteolysis are most likely the
physiologically relevant components in vivo. The pathophysio-
logic relevance of annexin 1 cleavage is strengthened by the
observation of elevated levels of N-terminally cleaved annexin 1
in bronchoalveolar lavage fluids from patients with cystic fibrosis
or other lung diseases compared to healthy volunteers [32–34].
Leukocyte proteases play a major role in acute inflammatory
disorders with or without bacterial involvement. Neutral serine
proteases such as human leukocyte elastase are stored in high
amounts in the primary granules of neutrophils. Whereas they
were commonly thought to be part of a relatively non-specific
degradation machinery for phagocytosed cell fragments or
microorganisms within the neutrophil lysosomes, it became
evident in recent years that they also function as important
regulators in the inflammatory process within the extracellular
milieu. Their abilities to proteolytically modulate cytokine
bioactivities by cytokine degradation (e.g. IL-6, TNF-α, IL-2),
cleavage of inactive precursor molecules leading to the release
of active cytokines (e.g. IL-1β, TNF-α, IL-8), cytokine receptor
shedding, and cleavage of cytokine binding proteins suggest a
role in the complex control of inflammation [9].
Degranulation and release of the cytotoxic degradative
enzymesmust be tightly controlled to prevent associated damage
of the surrounding host tissue. Adhesion of neutrophils to sub-
stratum seems to induce neutrophils to rapidly mobilize primary
granules upon stimulation with chemokines [20]. Neutrophils in
suspension show only limited degranulation. Therefore, priming
with cytochalasin B is needed to promote elastase release from
neutrophil granules upon stimulation with activating mediators
such as fMLF [35]. In this study, we could demonstrate a direct,
elastase-dependent proteolytic conversion of annexin 1 into a
truncated species by activated PMN. Although we focused here
on HLE, we cannot rule out the possibility that other PMN-
proteases could also account for the observed cleavage of
annexin 1. However, our data showed an almost complete
inhibition of annexin 1 cleavage by the specific HLE inhibitor.
Thus, it seems likely that the rapid cleavage of annexin 1
externalized from activated neutrophils that migrate into the
extravascular tissues is to a great extent dependent on elastase
activity. The controlled cleavage might be part of an appropriate
mechanism to control and limit the amount of inflammation
through proteolytic generation of anti-inflammatory mediators.
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